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However, this group of stakeholders is essentially rely-
ing on a comprehensive uncertainty analysis accompany-
ing disseminated conclusions and recommendations for an 
informed decision making. Only if this provision is met, 
risk managers, policy makers, and decision makers are able 
to fulfill their tasks and duties responsibly. Uncertainty 
comprises all types of limitations in the knowledge availa-
ble to assessors at the time an assessment is conducted and 
within the time and resources available for the assessment 
(EFSA Scientific Committee 2016). EFSA recommends 
that “assessments must say clearly and unambiguously 
what uncertainties have been identified and what is their 
impact on the overall assessment outcome.” This informa-
tion is missing in the respective booklet. EFSA has recog-
nized uncertainty analysis as a core element of transpar-
ency for all assessments and is of the opinion that “…as a 
general principle assessors are responsible for characteris-
ing uncertainty, while decision-makers are responsible for 
resolving the impact of uncertainty on decisions. Resolv-
ing the impact on decisions means deciding whether and 
in what way decision-making should take account of the 
uncertainty. Therefore, assessors need to inform decision-
makers about scientific uncertainty when providing their 
advice” (EFSA Scientific Committee 2016). We are in line 
with EFSA in this respect. In the present case, the GRACE 
consortium and/or its representatives take on the role as 
assessors and therefore are appealed for addressing uncer-
tainties which inherently affect their analyses in their final 
“Conclusions and Recommendations,” in the same booklet. 
This would substantially increase also the validity of and 
the confidence in the proposed “recommendations.”
Additionally, we miss a clearly structured description of 
the “strengths and limitations” of 90-day feeding trials in 
rodents and alternative studies as announced in the introduc-
tory section of the final “Conclusions and Recommendations” 
Over the past few years, Archives of Toxicology has pro-
vided excellent editorial coverage of the GRACE project 
and has issued—in accordance with the coordinators of 
the project—an invitation to an open scientific discussion 
on project-related subjects at several occasions (Hengstler 
2015).
We are now taking the opportunity to enter the forum by 
providing a comment in response to the final “Conclusions 
and Recommendations” published online by the GRACE 
consortium (GRACE Consortium 2015). The amount of 
data collected by the project team and the efforts profi-
ciently undertaken to solve the posed research questions 
are impressive and undisputedly acknowledged. However, 
it is astonishing that in this final report, the GRACE con-
sortium appears to have refrained from communicating 
uncertainties which intrinsically affect any scientific analy-
sis and subsequently the quality and validity of the drawn 
conclusions.
This observation is of special relevance when consid-
ering the envisioned primary target group of these final 
“Conclusions and Recommendations”: In contrast to peer-
reviewed publications of the GRACE consortium and as 
vaguely connoted in the heading of their booklet, this con-
tribution appears to be primarily tailored to address risk 
managers, policy makers, and decision makers.
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(GRACE Consortium 2015). A structured compilation of 
benefits and drawbacks of these research tools would have 
been a valuable asset in relieving the tasks of risk managers, 
policy makers, and decision makers.
However, we are confident that the GRACE consortium 
will be able to deliver this missing—but vital—information 
on uncertainties inherent to their conclusions to the deci-
sion makers at the European Commission which has the 
obligation to review in 2016 particular provisions in the 
Commission Implementing Regulation (EU) No 503/2013, 
based upon the results of the GRACE project (European 
Commission 2013).
We also would like to take the opportunity to elucidate 
some of our concerns as outlined in an internal commu-
nication between competent authorities and the European 
Commission and published by the GRACE consortium 
online (GRACE Consortium 2016). GRACE has been 
paradigmatically constructive by involving stakehold-
ers without reservations during most stages of the project. 
The transparent interaction and the open-minded dialogue 
between all involved parties during these phases of the pro-
ject is appreciated indeed and acknowledged.
However, coming to the key presentation (“Conclu-
sions and Recommendations”) of their project, GRACE 
appeared to have stopped halfway: Although stakeholder 
involvement is emphasized on several occasions in the 
booklet, GRACE refrains from reporting any discrepancies 
which had arisen during extended oral and written discus-
sions on the project design and on the interpretation of the 
results. Decision makers who have not closely monitored 
the evolution of the GRACE project and whose princi-
pal source of information on the topic might only be this 
respective booklet may get the impression that there have 
not been any discordances. It is clear that the booklet is 
not the appropriate forum for an extended presentation of 
stakeholder concerns. But avoiding any indication of aber-
rant opinions introduces a certain but unnecessary bias to 
this presentation. Referring only to web pages, incomplete 
databases, stakeholder reports, and papers which in several 
cases have not yet been published—without indicating any 
discordance—provides in our opinion only an insufficient 
basis for informed decision making. We are convinced that 
it was not the intention of the GRACE consortium to cre-
ate this impression deliberately, and are sure that they are 
willing to provide the necessary clarification for the risk 
management.
Additionally, concerning the relevance of 90-day whole 
food/feed studies in rodents, we are of the opinion that the 
final “Conclusions and Recommendations” suffer also from 
other shortcomings:
1. Limitations and weaknesses of the overall study 
approach (e.g., testing of only a single active principle; 
no empirical analysis of stacked events or GMOs with 
complex alterations of metabolic pathways or events 
coding for different modes of action) are not clearly 
communicated. However, this information is of cru-
cial importance for risk managers and for an informed 
decision making (EFSA Scientific Committee 2016). 
GRACE is only referring once to “intrinsic limita-
tions” inherent to 90-day whole food/feed studies in 
rodents without even explicitly elaborating on them in 
the booklet (GRACE Consortium 2015).
2. The “Conclusions and Recommendations” imply gen-
eral validity for the toxicological assessment of plant-
derived GMOs, but the project design was not intended 
to provide experimental evidence in support of these 
generalizations. “GRACE is expected to provide sound 
conclusions and recommendations on the adequacy of 
the approaches tested in the frame of GRACE” (see p. 
20; (GRACE Consortium 2015)) and, thus, is in the 
position to report results and conclusions on experi-
ence gained with MON810. But GRACE extrapolates 
far beyond this scope. This constitutes a bias which 
should be clearly communicated to the risk manag-
ers in the respective booklet as this is the basis for 
informed decision making.
3. GRACE highlights the importance of a “targeted and 
testable hypothesis” as trigger for animal experiments 
but does not communicate that unintended effects may 
be—in certain cases—unpredictable and unexpected 
and, thus, might not be detectable by a hypothesis-
driven approach.
4. In our opinion, the selection of certain project partners 
was not as optimal as would have been required by the 
demanding specific conditions related to toxicity test-
ing of GMOs in whole food and feed. In particular, the 
animal experimentation indicates some flaws which 
might have been relevant for the explanatory power 
of the results as a whole: The observation of circa-
dian effects during trial A and trial B [compare p. 24 
(GRACE Consortium 2015)] might be indicative for 
a non-optimal execution of these experiments, as this 
kind of effect would not have emerged if the studies 
were performed exactly according to OECD TG 408, 
EFSA 2011, and GLP requirements (EFSA 2011; 
OECD 1998). The necessity to include conventional 
control maize varieties (2 of them contaminated with 
MON810) as surrogates for missing historical control 
data is another indication for a non-optimal expertise 
on this type of whole food/feed studies in rodents.
5. A trend analysis considering trends and patterns in 
statistically nonsignificant differences (taking into 
account all applied diets, but not disregarding the pri-
mary importance of the comparison of GM and non-
GM near-isogenic control groups) is missing, although 
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this approach would provide valuable information. The 
analysis of trends is referred to in relevant guidelines 
(EFSA 2008).
6. In support of its conclusions, GRACE refers on sev-
eral occasions to the CADIMA database and to (envi-
sioned) scientific publications (GRACE Consortium 
2015). At the time of writing, the CADIMA database 
was not fully functional and contained only the data 
from trial A and trial B (database last accessed: June 
3, 2016). However, it is questionable whether a data-
base lacking a substantial part of the project results 
and unpublished papers are the appropriate basis for 
risk managers to decide in a timely manner on possible 
amendments of Commission Implementing Regulation 
503/2013 (European Commission 2013).
7. GRACE applied two conventional control maize vari-
eties which were contaminated with MON810 in fact 
constituting GM diets with a GM content of approxi-
mately 1 % (Zeljenkova et al. 2014). According to the 
European GMO legislation currently in force, these 
diets would have had to be labeled as being genetically 
modified (European Commission 2003). So it is at least 
questionable whether these contaminated varieties 
are eligible to establish historical control data which 
should be mandatorily generated by non-GM lines 
(EFSA 2011).
The detailed line of argumentation related to our con-
cerns as addressed above is provided as annex in the elec-
tronic supplemental material.
We do believe that the GRACE project provides a valua-
ble contribution in clarifying the relevance of 90-day whole 
food/feed studies in rodents for the risk assessment of 
transgenic plants intended for commercialization and that 
GRACE stands exemplary for stakeholder involvement in 
scientific research of immanent public interest.
But we are also of the opinion that the obtained results 
and the derived conclusions should be communicated in a 
way that also uncertainties, shortcomings, drawbacks, and 
limitations of the overall experimental setup are clearly 
transparent and readily accessible for those in charge of 
public health: the policy makers and decision makers and 
last but not least the risk managers of national and interna-
tional bodies.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
EFSA (2008) Safety and nutritional assessment of GM plants and 
derived food and feed: the role of animal feeding trials. Food 
Chem Toxicol 46(Suppl 1):S2–S70
EFSA (2011) Guidance for risk assessment of food and feed from 
genetically modified plants. EFSA Panel on Genetically Modi-
fied Organisms (GMO). EFSA J 9(5):2150
EFSA Scientific Committee (2016) Guidance on uncertainty in EFSA 
scientific assessment. Draft. Available from https://www.efsa.
europa.eu/sites/default/files/consultation/150618.pdf
European Commission (2003) Regulation (EC) 1830/2003 of the 
European Parliament and of the Council of 22 September 2003 
concerning the traceability and labelling of genetically modified 
organisms and the traceability of food and feed products pro-
duced from genetically modified organisms and amending Direc-
tive 2001/18/EC. Off J Eur Communities L268:24–28
European Commission (2013) Commission Implementing Regulation 
(EU) No 503/2013 of 3 April 2013 on applications for authori-
sation of genetically modified food and feed in accordance with 
Regulation (EC) No 1829/2003 of the European Parliament and 
of the Council and amending Commission Regulations (EC) No 
641/2004 and (EC) No 1981/2006 Text with EEA relevance. 
Available from http://eur-lex.europa.eu/legal-content/EN/
TXT/?uri=CELEX:32013R0503
GRACE Consortium (2015) Conclusions and recommendations on 
animal feeding trials and alternative approaches and on the use of 
systematic reviews and evidence maps for GMO impact assess-
ment. http://www.grace-fp7.eu/de/content/grace-published-its- 
final-conclusions-and-recommendations
GRACE Consortium (2016). Manuscript available from http://
www.grace-fp7.eu/de/content/open-letters-response-criticism- 
raised-austrian-authorities
Hengstler JG (2015) Invitation to an open scientific discussion. Arch 
Toxicol 89(1):1–2. doi:10.1007/s00204-014-1438-9
OECD (1998) Test No. 408: repeated dose 90-day oral toxicity study 
in rodents. OECD Publishing, Paris. Available from http://
www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-
90-day-oral-toxicity-study-in-rodents_9789264070707-en
Zeljenkova D, Ambrusova K, Bartusova M et al (2014) Ninety-day 
oral toxicity studies on two genetically modified maize MON810 
varieties in Wistar Han RCC rats (EU 7th Framework Pro-
gramme project GRACE). Arch Toxicol 88(12):2289–2314. 
doi:10.1007/s00204-014-1374-8
